Catabolic proinflammatory cytokines

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 1, Issue 3, 1998, Pages 245-251

  Argilés, Josep M ^a   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL; CACHEXIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK;

ANIMALS; ARTHRITIS, RHEUMATOID; CACHEXIA; CYTOKINES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; OBESITY; SEPSIS; SHOCK, SEPTIC;

EID: 0032057790     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199805000-00002     Document Type: Article

References (50)

1. Edwards PD, Moldawer LL. Role of cytokines in the metabolic response to stress. Curr Opin Clin Nutr Metab Care 1998; 1:187-190.
2. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24:163-172.
3. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 1997; 272:R621-R630.
4. Leon LR, Kozak W, Peschon J, Kluger MJ. Exacerbated febrile responses to LPS, but not turpentine, in TNF double receptor-knockout mice. Am J Physiol 1997; 272:R563-R569. A high dose of LPS resulted in exacerbated fevers in double TNF-α receptor-knockout mice compared with wild-type mice for the early and late phases of fever. A low dose of LPS, however, caused the same febrile reaction in both knockout and wild-type animals, suggesting that TNF-α modulates fevers to LPS dose dependently. In addition, TNF-α does not modulate fevers to a subcutaneous injection of turpentine.
5. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94:8093-8098.
6. Acton RD, Dahlberg PS, Uknis ME, Klaerner HG, Fink GS, Norman JG, Dunn DL. Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin-1 p80 receptors. Arch Surg 1996; 131:1216-1221.
7. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. New Engl J Med 1996; 334:1697-1702.
8. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-1538. A randomized controlled multicentre trial to evaluate the efficiency of blocking TNF-α in severe sepsis and septic shock shows that treatment of patients with the TNFR1 fusion protein does not decrease the mortality of severe septic patients.
9. Mazuski JE, Tolman K, Shapiro MJ. Effects of cytokine antagonists on the hepatic acute-phase response. J Surg Res 1997; 68:161-169.
10. Hill AG, Jacobson L, Gonzalez J, Rounds J, Majzoub JA, Wilmore DW. Chronic central nervous system exposure to interleukin-1β causes catabolism in the rat. Am J Physiol 1996; 271:R1142-R1148.
11. Plata-Salamán CR, Sonti G, Borkoski JP, Wilson CD, Ffrench-Mullen JMH. Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol Behav 1996; 60:867-875.
12. Sonti G, Ilyin SE, Plata-Salamán CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996; 270:R1394-R1402.
13. Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Fanelli FR. Cracking the riddle of cancer anorexia. Nutrition 1996; 12:706-710.
14. Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ III, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role of inflammatory anorexia. J Exp Med 1997; 185:171-175. Administration of proinflammatory cytokines such as TNF-α and IL-1 to mice results in increases in both serum leptin levels and leptin gene expression in fat, suggesting that leptin may represent one mechanism by which anorexia is induced during acute inflammatory conditions.
15. Frost RA, Lang CH, Gelato MC. Transient exposure of human myoblasts to tumor necrosis factor-α inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 1997; 138:4153-4159. Exposure of human myoblasts to TNF-α inhibits IGF-I-stimulated protein synthesis in a dose-dependent manner, suggesting that the anabolic actions of IGF-I on muscle protein synthesis may be impaired during catabolic conditions in which TNF-α is overexpressed.
16. Llovera M, García-Martínez C, Agell N, López-Soriano FJ, Argilés JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 1997; 230:238-241.
17. López-Soriano J, Llovera M, Carbó N, García-Martínez C, López-Soriano FJ, Argilés JM. Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. Mol Cell Endocrinol 1997; 132:93-99.
18. Ling PR, Schwartz JH, Bistrian BR. Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol 1997; 272:E333-E339.
19. Roe SY, Cooper AL, Morris ID, Hopkins SJ, Rothwell NJ. Involvement of cytokines in cachexia induced by T-cell leukaemia in the rat. Eur Cytokine Netw 1997; 8:45-49.
20. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97:244-249.
21. Kimura T, Sakaida I, Terai S, Matsumura Y, Uchida K, Okita K. Inhibition of tumor necrosis factor-α production retards liver regeneration after partial hepatectomy in rats. Biochem Biophys Res Commun 1997; 231:557-560.
22. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274:1379-1383. IL-6-deficient mice have impaired liver regeneration characterized by liver necrosis and failure, suggesting that this cytokine is a critical component of the regenerative response.
23. Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997; 5:130-135.
24. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997; 43:211-215.
25. Cederholm T, Wretlind B, Hellström K, Andersson B, Engström L, Brismar K, et al. Enhanced generation of interleukins 1β and 6 may contribute to the cachexia of chronic disease. Am J Clin Nutr 1997; 65:876-882.
26. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96:526-534.
27. Zhao SP, Zeng LH. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int J Cardiol 1997; 58:257-261.
28. Luheshi GN, Stefferl A, Turnbull AV, Dascombe MJ, Brouwer S, Hopkins SJ, Rothwell NJ. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-α in the rat. Am J Physiol 1997; 272:R862-R868.
29. Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-α-induced skin inflammation. Eur J Immunol 1997; 27:1713-1718.
30. Kalden-Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kaldfen JR. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-α monoclonal antibody therapy. Rheumatol Int 1997; 16:249-255.
31. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 1997; 105:257-263.
32. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-147.
33. Argilés JM, López-Soriano J, Busquets S, López-Soriano FJ. Journey from cachexia to obesity by TNF. FASEB J 1997; 11:743-751.
34. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389:610-614.
35. Pfeiffer A, Janott J, Möhlig M, Ristow M, Rochlitz H, Busch K, et al. Circulating tumor necrosis factor a is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 1997; 29:111-114.
36. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997; 46:451-455.
37. Kroder G, Bossenmayer B, Kellerer M, Capp E, Stoyanov B, Muhlhofer A, et al. Tumor necrosis factor a and hyperglycemia-induced insulin resistance. J Clin Invest 1996; 97:1471-1477.
38. Peraldi P, Hotamisligil GS, Buurman VVA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996; 271:13018-13022.
39. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest 1997; 100:1863-1869. Thiazolidinediones, a new class of drugs that can be used to improve insulin resistance in type II diabetes, can block the reduction of tyrosine phosphorylation of insulin receptor and insulin receptor substrate caused by TNF-α in adipose cells.
40. López-Soriano J, López-Soriano FJ, Bagby GJ, Williamson DH, Argilés JM. Anti-TNF treatment does not reverse the abnormalities in lipid metabolism of the obese Zucker rat. Am J Physiol 1997; 272:E656-E660.
41. Fürnsinn C, Neschen S, Wagner O, Roden M, Bisschop M, Waldhäusl W. Acute and chronic exposure to tumor necrosis factor-α fails to affect insulin-stimulated glucose metabolism of isolated rat soleus muscle. Endocrinology 1997; 138:2674-2679.
42. Bedard S, Marcotte B, Marette A. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J 1997; 325:487-493.
43. Hirokawa J, Sakaue S, Tagami S, Kawakami Y, Sakai M, Nishi S, Nishihira J. Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-α. Biochem Biophys Res Commun 1997; 235:94-98.
44. Dahlberg PS, Acton RD, Battafarano RJ, Uknis ME, Ratz CA, Johnston JW, et al. A novel endotoxin antagonist attenuates tumor necrosis factor-α secretion. J Surg Res 1996; 63:44-48.
45. Yamamoto N, Sakai F, Yamazaki H, Sato N, Nakahara K, Okuhara M. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock. Eur J Pharmacol 1997; 327:169-174.
46. Eliaz R, Wallach D, Kost J. Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor. Cytokine 1996; 8:482-487.
47. Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ. IL-4 protects against TNF-α-mediated cachexia and death during acute schistosomiasis. J Immunol 1997; 159:777-785.
48. Zisman DA, Kunkel SL, Strieter RM, Tsai WC, Bucknell K, Wilkowski J, Standiford TJ. MCP-1 protects mice in lethal endotoxemia. J Clin Invest 1997; 99:2832-2836.
49. Nicoletti F, Mancuso G, Cusumano V, Di Marco R, Zaccone P, Bendtzen K, Teti G. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. Eur J Immunol 1997; 27:1580-1583.
50. Fujiki F, Mukaida N, Hirose K, Ishida H, Harada A, Ohno S, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997; 57:94-99.